Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New US ambulatory electrocardiograph standard:

This article was originally published in Clinica

Executive Summary

The Association for the Advancement of Medical Instrumentation (AAMI) in the US has released a revision of the Ambulatory Electrocardiographs American National Standard which focuses on minimum requirements for safety and effectiveness of ECG equipment. Approved by the American National Standards Institute, the revised ANSI/AAMI EC38 standard covers how to effectively obtain a cardiac rhythm signal from the surface of a patient's body and transmit the signal to a recording device. Updates to the document include changes to the sections pertaining to stationary equipment, defibrillator energy shunting and an expanded section on electromagnetic compatibility. It will be especially useful to device purchasers, says AAMI, because it provides a precise description of the characteristics and limitations of ambulatory ECG equipment.

You may also be interested in...



ICER Partnering With Aetion To Scale Up Use Of RWE In Value Assessments

Aetion is also working with the US Food and Drug Administration and a number of biopharma companies on projects involving use of real-world evidence.

‘Highly Questionable’ GMP Compliance In Pakistan Prompts New Licensing System

Increased fines and penalties are on the cards for manufacturing facilities that fail to comply with proposed new requirements.

Infographic: 20 Years Of Mega-Deals

The biopharma sector is often accused of a being a slow-moving engine, but a look back over the last 20 years reveals that a lot has changed. In Vivo explores the history of high-impact M&A transactions in the industry between 1999 and 2019. 

Topics

UsernamePublicRestriction

Register

MT080175

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel